Paolo Pozzilli

COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS

Robert Altman, L Carreras, Rubén Sierra Díaz et al. · Oxford University Research Archive (ORA) (University of Oxford) · 1994 · 3.3K citations

Medicine, Pharmacology, Pharmacotherapy +10

C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve β-Cell Function

Jerry P. Palmer, G. Alexander Fleming, Carla J. Greenbaum et al. · Diabetes · 2004 · 484 citations · Full text

Medicine, Endocrinology, Immunology +17

A functional variant of SUMO4, a new IκBα modifier, is associated with type 1 diabetes

Dehuang Guo, Manyu Li, Yan Zhang et al. · Nature Genetics · 2004 · 422 citations

Life Sciences, Biochemistry, Molecular Biology +12

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes

Satish K. Garg, Robert R. Henry, Phillip Banks et al. · New England Journal of Medicine · 2017 · 416 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

Antoinette Moran, Brian N. Bundy, Dorothy Becker et al. · The Lancet · 2013 · 354 citations · Full text

Medicine, Endocrinology, Immunology +14